v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF SERIES C PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Orphai Therapeutics [Member]
Private Placement
At The Market Offering
Series C Preferred Stock
Series C Preferred Stock
Orphai Therapeutics [Member]
Series C Preferred Stock
Private Placement
Common Stock
Common Stock
Orphai Therapeutics [Member]
Common Stock
Private Placement
Common Stock
At The Market Offering
Additional Paid in Capital
Additional Paid in Capital
Orphai Therapeutics [Member]
Additional Paid in Capital
Private Placement
Additional Paid in Capital
At The Market Offering
Accumulated Other Comprehensive Income / (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024 [1]               220,009                  
Beginning balance at Dec. 31, 2024 $ 30,146             $ 0 [1]       $ 406,653 [1]       $ (35) $ (376,472)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of stock (in shares) [1]                   33,360 13,833            
Issuance of stock     $ 746 $ 2,890                   $ 746 [1] $ 2,890 [1]    
Issuance of common stock on exercise of stock options (in shares) [1]               920                  
Issuance of common stock on exercise of stock options 183                     183 [1]          
Stock based compensation 2,659                     2,659 [1]          
Foreign currency translation adjustments 6,261                             6,261  
Unrealized gain (loss) on available for sale investments (70)                             (70)  
Net Income (Loss) (31,079)                               (31,079)
Ending balance (in shares) at Jun. 30, 2025 [2]               268,122                  
Ending balance (in shares) at Jun. 30, 2025         0                        
Ending balance at Jun. 30, 2025 11,736             $ 0 [2]       413,131 [2]       6,156 (407,551)
Ending Balance at Jun. 30, 2025         $ 0                        
Beginning balance (in shares) at Mar. 31, 2025 [2]               220,446                  
Beginning balance (in shares) at Mar. 31, 2025         0                        
Beginning balance at Mar. 31, 2025 18,581             $ 0 [2]       408,126 [2]       1,957 (391,502)
Beginning Balance at Mar. 31, 2025         $ 0                        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of stock (in shares) [2]                   33,360 13,833            
Issuance of stock     $ 746 2,890                   $ 746 [2] 2,890 [2]    
Issuance of common stock on exercise of stock options (in shares) [2]               483                  
Issuance of common stock on exercise of stock options 96                     96 [2]          
Stock based compensation [2] 1,273                     1,273          
Foreign currency translation adjustments 4,216                             4,216  
Unrealized gain (loss) on available for sale investments (17)                             (17)  
Net Income (Loss) (16,049)                               (16,049)
Ending balance (in shares) at Jun. 30, 2025 [2]               268,122                  
Ending balance (in shares) at Jun. 30, 2025         0                        
Ending balance at Jun. 30, 2025 $ 11,736             $ 0 [2]       413,131 [2]       6,156 (407,551)
Ending Balance at Jun. 30, 2025         $ 0                        
Beginning balance (in shares) at Dec. 31, 2025 278,627             278,627 [1]                  
Beginning balance (in shares) at Dec. 31, 2025 0       0                        
Beginning balance at Dec. 31, 2025 $ (35,714)             $ 0 [1]       418,987 [1]       5,750 (460,451)
Beginning Balance at Dec. 31, 2025         $ 0                        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of stock (in shares)           67,101.235 144,200.633   162,971 [1]   526,435 [1]            
Issuance of stock   $ 3,242   20,338   $ 48,146 $ 95,665       $ 1 [1]   $ 3,242 [1]   20,337 [1]    
Issuance of common stock on exercise of stock options (in shares) [1]               9,989                  
Issuance of common stock on exercise of stock options 341                     341 [1]          
Fractional shares round up due to June 2026 Reverse Stock Split , shares [1]               39,041                  
Fair value of replacement awards issued as consideration in Orphai Acquisition   4,161                     4,161 [1]        
Stock based compensation 13,379                     13,379 [1]          
Foreign currency translation adjustments (1,490)                             (1,490)  
Unrealized gain (loss) on available for sale investments (5)                             (5)  
Net Income (Loss) $ (39,576)                               (39,576)
Ending balance (in shares) at Jun. 30, 2026 1,017,063             1,017,063 [2]                  
Ending balance (in shares) at Jun. 30, 2026 211,301.868       211,301.868                        
Ending balance at Jun. 30, 2026 $ (35,324)             $ 1 [2]       460,447 [2]       4,255 (500,027)
Ending Balance at Jun. 30, 2026         $ 143,811                        
Beginning balance (in shares) at Mar. 31, 2026 [2]               689,541                  
Beginning balance (in shares) at Mar. 31, 2026         0                        
Beginning balance at Mar. 31, 2026 15,672             $ 1 [2]       435,600 [2]       4,610 (424,539)
Beginning Balance at Mar. 31, 2026         $ 0                        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                  
Issuance of stock (in shares)           67,101.235 144,200.633   162,971 [2]   125,510 [2]            
Issuance of stock   3,242   $ 5,351   $ 48,146 $ 95,665           3,242 [2]   $ 5,351 [2]    
Fractional shares round up due to June 2026 Reverse Stock Split , shares [2]               39,041                  
Fair value of replacement awards issued as consideration in Orphai Acquisition   $ 4,161                     $ 4,161 [2]        
Stock based compensation 12,093                     12,093 [2]          
Foreign currency translation adjustments (355)                             (355)  
Unrealized gain (loss) on available for sale investments 0                                
Net Income (Loss) $ (75,488)                               (75,488)
Ending balance (in shares) at Jun. 30, 2026 1,017,063             1,017,063 [2]                  
Ending balance (in shares) at Jun. 30, 2026 211,301.868       211,301.868                        
Ending balance at Jun. 30, 2026 $ (35,324)             $ 1 [2]       $ 460,447 [2]       $ 4,255 $ (500,027)
Ending Balance at Jun. 30, 2026         $ 143,811                        
[1]

(1) Adjusted prior period common stock and additional paid-in-capital to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026.
[2]

(1) Adjusted prior period common stock and additional paid-in-capital to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026.